NetworkNewsWire Announces Publication on Investment Opportunities Created by Ongoing R&D of Medical Cannabis  

NEW YORK, Dec. 04, 2017 (GLOBE NEWSWIRE) -- NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring Veritas Pharma Inc. (CSE:VRT) (OTC:VRTHF) (FRT:2VP), an emerging-stage pharmaceutical and IP development company that, through its 80% owned Cannevert Therapeutics Ltd. ("CTL") subsidiary, seeks to develop the most effective cannabis strains (cultivars) specific to pain, nausea, epilepsy and PTSD, solving the critical need for clinical data to support medical marijuana claims.

The publication, titled, “Investors Could Reap Global Rewards of Research into Medical Cannabis Science,” highlights focused and increased efforts in the research and development of the use of cannabis for a variety of medicinal purposes.

To view the full publication, visit: https://www.networknewswire.com/investors-reap-global-rewards-research-medical-cannabis-science/

“With cannabis set to become legal for recreational use in July 2018 in Canada, and usage of the product for medical purposes steadily rising both in Canada and worldwide, cannabis companies have ramped up their efforts to make new scientific discoveries related to the plant’s medical uses. Among companies seeking to produce clinical data to validate medical marijuana claims, Veritas Pharma (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) has carved its own niche with a multi-front approach to identifying the potential of its cannabis products for ameliorating a variety of maladies, including pain, nausea, epilepsy and PTSD. …

“Further expanding its research and addressing the global need for safe and effective cancer treatments, Veritas recently hired Dr. Dimitri Petchkovski of Fibroblast Consulting to spearhead its investigation into use of Veritas’ cannabis strains in lung, prostate, colon, breast, and melanoma cancer cell lines.

“In Canada alone, there were more than 200,000 new cases of cancer and nearly 81,000 cancer-related deaths in 2017, according to Canadian Cancer Statistics 2017. Despite considerable need for effective therapies, the market lacks sufficient scientific evidence to demonstrate cannabis or cannabinoids can cut the risk of cancer. While most cancer scientists focus on understanding how different cancers respond to specific compounds in cannabis, Veritas’ approach will be to quickly access more cannabis varieties, systematically profile the effects of the whole plant using various in vitro and in vivo animal models of cancer alongside standard drugs, and quickly conduct a clinical trial.”

About Veritas Pharma Inc.

Veritas Pharma Inc. is an emerging pharmaceutical and IP development company, who, through its 80% owned subsidiary Cannevert Therapeutics Ltd. ("CTL"), is advancing the science behind medical cannabis. It is the company’s aim, through its investment in CTL, to develop the most effective cannabis strains (cultivars) specific to pain, nausea, epilepsy and PTSD, solving the critical need for clinical data to support medical marijuana claims. CTL’s unique value proposition uses a low-cost research and development model to help drive shareholder value, and speed-to-market. Veritas investment in CTL is led by strong management team, bringing together veteran academic pharmacologists, anesthetists & chemists. The company's commercial mission is to patent protect IP (cultivars & strains) and sell or license to cancer clinics, insurance industry and pharma, targeting multi-billion-dollar global markets. For more information, visit the company’s website at www.VeritasPharmaInc.com.

About NetworkNewsWire

NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today's market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

For more information please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company's SEC filings. These risks and uncertainties could cause the company's actual results to differ materially from those indicated in the forward-looking statements.

NNW Contact:

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com